ClinicalTrials.gg
CompletedNCT00534248Updated Apr 12, 2017Results posted

Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

A Phase 3 interventional study of Zoster Vaccine, Live (Zostavax™) and Comparator: Placebo in Shingles, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22,439
Allocation
Randomized
Ages
50 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
Largest of 29
22,439 · median 160
Started
2007
with 3 others
Phase 3
9 of 29
none open now
Registered
4th of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one has the largest enrollment, is one of 4 that started in 2007, is one of 9 in phase 3, and was the 4th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

This study will look at how well Zostavax™ works in preventing shingles in participants ages 50-59 years old.

03

Conditions studied

  • Shingles

Browse trials for

04

Who can participate

Ages eligible
50 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be between 50 - 59 years of age
  • No fever on day of vaccination
  • Females of must be willing to use acceptable form of

Exclusion criteria

Exclusion Criteria:

  • Have received chicken pox or shingles vaccine
  • Have already had shingles
  • Have recently had another vaccination
  • Pregnant or breast feeding. Have participated in another research study in the last 30 days
  • You are taking certain antiviral drugs
  • History of allergic reaction to any vaccine component, including gelatin or neomycin
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
22,439 participants (actual)

Study arms

  • Experimental
    Zostavax™

    Participants randomized to receive Zoster Vaccine, Live (Zostavax™).

    Biological: Zoster Vaccine, Live (Zostavax™)

  • Placebo comparator
    Placebo

    Participants randomized to receive Placebo.

    Biological: Comparator: Placebo

Interventions

  • A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.

    Also known as: V211, Zostavax™

  • BiologicalComparator: Placebo

    A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.

06

What researchers measure

Primary outcomes

  1. Incidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group

    Incidence rate of HZ cases was defined as the number of confirmed HZ cases per 1000 person-years of follow-up following vaccination. Vaccine efficacy for HZ was defined as the relative reduction in incidence rate of HZ in the group that received Zostavax™ compared with the group that received placebo based on the intent-to-treat population.

    Time frame: 2 Years

Secondary outcomes

  1. Varicella-zoster Virus (VZV) Antibody Response at 6 Weeks Post Vaccination by Vaccination Group

    VZV antibody response as measured by Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) in the group that received Zostavax™ compared with the group that received placebo, based on the random subcohort population.

    Time frame: 6 Weeks

  2. Number of Participants Reporting One or More Serious Adverse Experiences by Vaccination Group During the 42-day Postvaccination Follow-up Period

    A serious adverse event is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.

    Time frame: Through 42 days post-vaccination

07

Results

Posted May 2, 2011

Participant flow

Participant flow — Overall Study
MilestoneZostavax™Placebo
Started1121111228
Vaccinated1118611210
Completed1055010555
Not completed661673
Withdrew: Adverse event1929
Withdrew: Lost to follow-up353375
Withdrew: Other protocol specified criteria133
Withdrew: Physician decision107
Withdrew: Protocol violation34
Withdrew: Withdrawal by subject263255

Outcome measures

PrimaryIncidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group

Incidence rate of HZ cases was defined as the number of confirmed HZ cases per 1000 person-years of follow-up following vaccination. Vaccine efficacy for HZ was defined as the relative reduction in incidence rate of HZ in the group that received Zostavax™ compared with the group that received placebo based on the intent-to-treat population.

Time frame:
2 Years
Reported as:
Mean · number of HZ cases/1000 person-years
Incidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group
number of HZ cases/1000 person-yearsZostavax™Placebo
Incidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group1.994 (1.346 to 2.847)6.596 (5.361 to 8.030)
Statistical analysis
  • Zostavax™ vs Placebo · Conditional Exact Method · p = <.001 · Point estimate: .698 · 95% CI .541 to .806The point estimate was for vaccine efficacy with respect to incidence of HZ.
SecondaryVaricella-zoster Virus (VZV) Antibody Response at 6 Weeks Post Vaccination by Vaccination Group

VZV antibody response as measured by Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) in the group that received Zostavax™ compared with the group that received placebo, based on the random subcohort population.

Time frame:
6 Weeks
Reported as:
Mean · gpELISA units/mL
Varicella-zoster Virus (VZV) Antibody Response at 6 Weeks Post Vaccination by Vaccination Group
gpELISA units/mLZostavax™Placebo
Varicella-zoster Virus (VZV) Antibody Response at 6 Weeks Post Vaccination by Vaccination Group660.0 (624.7 to 697.2)293.1 (274.7 to 312.6)
Statistical analysis
  • Zostavax™ vs Placebo · linear mixed longitudinal analysis model · p = <.001 · Geometric mean titre ratio: 2.3 · 95% CI 2.2 to 2.4
SecondaryNumber of Participants Reporting One or More Serious Adverse Experiences by Vaccination Group During the 42-day Postvaccination Follow-up Period

A serious adverse event is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.

Time frame:
Through 42 days post-vaccination
Reported as:
Number · participants
Number of Participants Reporting One or More Serious Adverse Experiences by Vaccination Group During the 42-day Postvaccination Follow-up Period
participantsZostavax™Placebo
Number of Participants Reporting One or More Serious Adverse Experiences by Vaccination Group During the 42-day Postvaccination Follow-up Period69 (.48 to .79)61 (.42 to .70)
Statistical analysis
  • Zostavax™ vs Placebo · Relative risk: 1.133 · 95% CI .805 to 1.595

Adverse events

Collected over Serious adverse events (SAEs) are presented that occurred from Day 1 to 182 postvaccination. Deaths that occurred any time during the study are also included. Non-serious AEs are presented for events that occurred from Day 1 to 42 postvaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zostavax™—243/11,094 (2.2%)7,228/11,094 (65.2%)
Placebo—233/11,116 (2.1%)2,183/11,116 (19.6%)
Most frequent serious events
Showing 10 of 285
Most frequent serious events
EventZostavax™Placebo
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)14/1109410/11116
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/110947/11116
PneumoniaInfections and infestations4/110948/11116
Chest painGeneral disorders7/110947/11116
Non-cardiac chest painGeneral disorders5/110947/11116
AppendicitisInfections and infestations6/110947/11116
Atrial fibrillationCardiac disorders2/110946/11116
Cardiac failure congestiveCardiac disorders5/110941/11116
Myocardial infarctionCardiac disorders4/110945/11116
CellulitisInfections and infestations2/110945/11116
Most frequent other events
Most frequent other events
EventZostavax™Placebo
Injection site painGeneral disorders6005/110941025/11116
Injection site erythemaGeneral disorders5351/11094483/11116
Injection site swellingGeneral disorders4500/11094309/11116
Injection site pruritusGeneral disorders1287/1109478/11116
HeadacheNervous system disorders1041/11094917/11116

Baseline characteristics

Age, Continuous
Age, Continuous(years)Zostavax™PlaceboTotal
Mean54.9 ± 2.854.8 ± 2.854.8 ± 2.8
Sex: Female, Male
Sex: Female, Male(Participants)Zostavax™PlaceboTotal
Female6913697213885
Male429842568554
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Gilbert PB, Gabriel EE, Miao X, Li X, Su SC, Parrino J, Chan IS. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis. 2014 Nov 15;210(10):1573-81. doi: 10.1093/infdis/jiu279. Epub 2014 May 13. PubMed 24823623 ↗
  • Levin MJ, Schmader KE, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis. 2013 Nov 1;208(9):1386-90. doi: 10.1093/infdis/jit342. Epub 2013 Aug 1. PubMed 23908486 ↗
  • Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012 Apr;54(7):922-8. doi: 10.1093/cid/cir970. Epub 2012 Jan 30. PubMed 22291101 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2007
First posted
Sep 24, 2007
Start
Oct 2007
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
May 2, 2011
Last update
Apr 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00534248
Responsible party
Sponsor
First posted
Sep 24, 2007
Start date
Oct 2007
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
May 2, 2011
Last update
Apr 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion